| Literature DB >> 10450972 |
R C Buijsman1, J E Basten, T G van Dinther, G A van der Marel, C A van Boeckel, J H van Boom.
Abstract
The synthesis of a novel antithrombotic consisting of a heparin pentasaccharide conjugated to the active site inhibitor N-(2-naphtalenesulfonyl)-glycyl-(D)-4-aminophenyl-alanyl-piperidin e (NAPAP) (i.e. compound I) is reported. This conjugate shows a unique pharmacological profile both in vitro and in vivo having direct anti-thrombin and ATIII-mediated anti-Xa activity. Furthermore, conjugate I has a prolonged in vivo half-life compared to NAPAP (1.5 h vs 9 min.).Entities:
Mesh：
Substances：
Year: 1999 PMID： 10450972 DOI： 10.1016/s0960-894x(99)00320-0
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823